New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...

Not intended for US and UK audiencesBI 765423 has been developed to target IL-11, a key driver of fibrosisNew study will investigate potential of ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...

Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

LTI-03 is designed to protect and restore the function of the oxygen uptake cells and control lung fibrosis. Credit: SewCreamStudio / Shutterstock. US-based biopharmaceutical company Rein Therapeutics ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...